Please login to the form below

Not currently logged in
Email:
Password:

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

CRUK forges £30m ‘post-Brexit’ R&D alliance

CRUK forges £30m ‘post-Brexit’ R&D alliance

One UK project – called HUNTER - is getting £5m to look into immunotherapies for liver cancer and will be led by Newcastle University. ... The University of Trento is leading on a project worth around £5m to develop a blood test for advanced prostate

Latest news

More from news
Approximately 9 fully matching, plus 212 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Taking a strategic approach Taking a strategic approach

    proposed submitting further evidence and an amended patient access scheme for its prostate cancer drug. ... In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers. ... 85. Agios Pharmaceuticals / Celgene. R&D collaboration and profit share. AG-881 IDH (isocitrate dehydrogenase) mutant

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... which comes off patent

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Increasing the speed of knowledge sharing in blood cancer to improve patient care. ... Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities.

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Increasing the speed of knowledge sharing in blood cancer to improve patient care. ... Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities.

  • THE OTHER SIDE OF...BLOOD CANCER

    participant. THE OTHER SIDE OF … BLOOD CANCER. “ I’ m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’ s time is limited.

  • THE OTHER SIDE OF...BLOOD CANCER

    participant. THE OTHER SIDE OF … BLOOD CANCER. “ I’ m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’ s time is limited.

  • Cancer communications; it's in our blood

    Cancer communications; it's in our blood. We have years of experience working in cancer communications, partnering with some of the biggest brands, institutions and societies. ... From solid tumours to blood cancer, from patients to professionals; within

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics